Page 4 - Kaplan Meier News Today : Breaking News, Live Updat

Answers to critics: Why there is a long term toxicity due to NK603 Roundup-tolerant genetically modified maize and to a Roundup herbicide

Published: June 13, 2023

Universally Available Gilles-Eric Séralini, , Robin Mesnage, Nicolas Defarge, Steeve Gress University of Caen, Institute of Biology, EA2608, CRIIGEN and Network on Risks, MRSH-CNRS, Esplanade de la Paix, 14032 Caen Cedex, France Didier Hennequin University of Caen, Network on Risks, MRSH-CNRS, Bd Maréchal Juin, 14032 Caen Cedex, France Emilie Clair University of Caen, Institute of…

Source: engineeringevil.com

Cabozantinib Plus Nivolumab and Ipilimumab Elicits Meaningful Activity in RCCvh

Published: June 4, 2023

Triplet therapy with cabozantinib, nivolumab, and ipilimumab demonstrated clinical meaningful activity in patients with renal cell carcinoma with variant histologies.

Source: onclive.com

Jazz Pharmaceuticals plc: Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers

Published: June 3, 2023

Results presented today at ASCO 2023 and concurrently published in The Lancet Oncology demonstrate meaningful clinical benefit including antitumor activity, confirmed objective response rate

Source: finanznachrichten.de

$Intensity Therapeutics' INT230-6 Prolongs Survival Alone or in Combination With Ipilimumab in Adult Patients with Relapsed, Refractory, Metastatic Sarcomas - Vimarsana News$

Intensity Therapeutics' INT230-6 Prolongs Survival Alone or in Combination With Ipilimumab in Adult Patients with Relapsed, Refractory, Metastatic Sarcomas

Published: June 3, 2023

/PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity"), a clinical-stage biotechnology company focused on the discovery and development of proprietary,...

Source: prnewswire.com

Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers

Published: June 2, 2023

Results presented today at ASCO 2023 and concurrently published in The Lancet Oncology demonstrate meaningful clinical benefit including antitumor activity,...